Alnylam announces date of planned fda advisory committee meeting for onpattro® (patisiran) for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the u.s. food and drug administration (fda) has set a date of september 13, 2023 for the meeting of the cardiovascular and renal drugs advisory committee to review the supplemental new drug application for patisiran, an investigational treatment for the cardiomyopathy of transthyretin-mediated (attr) amyloidosis. as previously announced, the fda has set an.
ALNY Ratings Summary
ALNY Quant Ranking